Piper Sandler Maintains Overweight on Karyopharm Therapeutics, Lowers Price Target to $7

Benzinga Newsdesk www.benzinga.com Negative 88.4%

Neg 88.4% Neu 0% Pos 0%

Piper Sandler analyst Edward Tenthoff maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Overweight and lowers the price target from $16 to $7.